Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the ongoing Phase 1/2 study evaluating Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in relapsed/refractory extensive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Gocatamig (MK-6070)
• Ifinatamab Deruxtecan (I-DXd) (I-DXd)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING